4 new drugs of natural medicine: citrus fruit rheumatism analgesic gel paste (Babu agent) applied for clinical acceptance
-
Last Update: 2014-07-24
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Citrus spinosa is a typical desert medicinal plant, which grows mainly in gravelly slopes It is a folk medicine of Uygur nationality in Xinjiang Because of the traditional medicinal root bark, the long-term mining of root bark has caused severe challenges to the medicinal resources and desert ecology The Xinjiang Uygur Autonomous Region Science and technology support program project "Research on new medicinal parts and anti rheumatism preparations of Uighur medicine ciyama" undertaken by Xinjiang Pharmaceutical Research Institute, takes the fruit of ciyama with strong regeneration ability as the research object, conducts systematic research on its bioactive components and its efficacy, toxicity (including reproductive toxicity), general pharmacology, etc., and develops A new formulation for transdermal administration - cataplasm This dosage form not only plays the anti rheumatism and anti-inflammatory slow-release effect of the active ingredients, but also effectively solves the skin irritation problem It is also the first time that this dosage form has been applied in Xinjiang ethnic medicine research The project team lasted nearly 5 years, and completed the preclinical research work of "thorn nut nut rheumatism analgesic gel paste (Babu agent)", and received the notification of acceptance of the 4 clinical application of new natural medicines issued by the State Food and drug administration This is the first national registration application for class 4 new natural drugs in Xinjiang, and also the research and development of a small number of class 4 new drugs in China At present, the drug variety has entered the technical review link organized by the drug review center of the State Food and drug administration, and is expected to obtain the drug clinical research approval in the next two years Recently, the project has successfully passed the financial acceptance and technical acceptance organized by Xinjiang science and technology department.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.